BR112019003976A2 - anticorpos anti-tim-3 e seu uso - Google Patents

anticorpos anti-tim-3 e seu uso

Info

Publication number
BR112019003976A2
BR112019003976A2 BR112019003976A BR112019003976A BR112019003976A2 BR 112019003976 A2 BR112019003976 A2 BR 112019003976A2 BR 112019003976 A BR112019003976 A BR 112019003976A BR 112019003976 A BR112019003976 A BR 112019003976A BR 112019003976 A2 BR112019003976 A2 BR 112019003976A2
Authority
BR
Brazil
Prior art keywords
antibodies
tim
thymic
domain
mucin
Prior art date
Application number
BR112019003976A
Other languages
English (en)
Inventor
Peng Hao
Li Kang
Xue Liu
Wei Min
Liu Qi
Zhang Tong
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of BR112019003976A2 publication Critical patent/BR112019003976A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a presente invenção refere-se a anticorpos que se ligam especificamente ao domínio de imunoglobulina de células t e domínio de mucina 3 (tim-3). os anticorpos anti-tim-3 podem ser usados para tratar, prevenir ou diagnosticar doenças imunológicas, cancerígenas, infecciosas ou outros distúrbios patológicos que podem ser modulados por funções mediadas por tim-3.
BR112019003976A 2016-08-26 2017-08-25 anticorpos anti-tim-3 e seu uso BR112019003976A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016096924 2016-08-26
PCT/CN2017/099098 WO2018036561A1 (en) 2016-08-26 2017-08-25 Anti-tim-3 antibodies and use thereof

Publications (1)

Publication Number Publication Date
BR112019003976A2 true BR112019003976A2 (pt) 2019-05-28

Family

ID=61246369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003976A BR112019003976A2 (pt) 2016-08-26 2017-08-25 anticorpos anti-tim-3 e seu uso

Country Status (15)

Country Link
US (3) US11203637B2 (pt)
EP (2) EP3970749A1 (pt)
JP (2) JP6968872B2 (pt)
KR (1) KR102460525B1 (pt)
CN (3) CN116655790A (pt)
AU (1) AU2017317227A1 (pt)
BR (1) BR112019003976A2 (pt)
CA (1) CA3034962A1 (pt)
EA (1) EA201990594A1 (pt)
MX (1) MX2019002242A (pt)
NZ (1) NZ751246A (pt)
SG (2) SG10201912199XA (pt)
TW (2) TW202246347A (pt)
WO (1) WO2018036561A1 (pt)
ZA (1) ZA201901113B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) * 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
CN116655790A (zh) 2016-08-26 2023-08-29 百济神州有限公司 抗tim-3抗体及其用途
EP3535586A4 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3)
JP7118073B2 (ja) 2017-01-09 2022-08-15 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2019179420A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-tim-3 antibodies
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
EP3842071A4 (en) * 2018-08-20 2022-05-25 Jiangsu Hengrui Medicine Co., Ltd. USE OF TIM-3 ANTIBODIES IN THE MANUFACTURE OF PHARMACEUTICALS FOR THE TREATMENT OF TUMORS
MX2020013428A (es) * 2018-08-21 2021-07-16 Albert Einstein College Of Medicine Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
US20230279105A1 (en) * 2019-06-21 2023-09-07 Single Cell Technology, Inc. Anti-tim-3 antibodies
CN110498855A (zh) * 2019-07-25 2019-11-26 钟小泉 一种tim-3抗体及其用途
US20230002501A1 (en) * 2019-11-21 2023-01-05 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CN111995681B (zh) * 2020-05-09 2022-03-08 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
CN112940126A (zh) * 2021-03-12 2021-06-11 北京广未生物科技有限公司 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
JP2024516616A (ja) * 2021-04-23 2024-04-16 スゾウ ネオロジクス バイオサイエンス シーオー．， エルティーディー． Ｔｉｍ－３を標的とする抗体及びその使用
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
WO2024041652A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment
WO2024041651A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1406653A4 (en) * 2001-06-29 2005-05-04 Univ Leland Stanford Junior T-LYMPHOCYTE REGULATORY GENES AND METHODS OF USE
EP1467759A4 (en) 2002-01-30 2006-05-31 Brigham & Womens Hospital COMPOSITIONS AND METHODS ASSOCIATED WITH TIM-3, TH1-SPECIFIC CELL SURFACE MOLECULE
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
WO2009155609A1 (en) 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
CN102492038B (zh) * 2011-12-09 2014-05-28 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
CN105792836A (zh) * 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN103721255A (zh) * 2014-01-07 2014-04-16 苏州大学 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
SG11201703403TA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
KR102011205B1 (ko) * 2014-11-06 2019-08-14 에프. 호프만-라 로슈 아게 항-tim3 항체 및 사용 방법
CN116655790A (zh) 2016-08-26 2023-08-29 百济神州有限公司 抗tim-3抗体及其用途

Also Published As

Publication number Publication date
SG11201901548SA (en) 2019-03-28
CN109790218B (zh) 2023-03-03
EP3504243A1 (en) 2019-07-03
ZA201901113B (en) 2020-10-28
NZ751246A (en) 2023-04-28
CN109790218A (zh) 2019-05-21
JP2022027659A (ja) 2022-02-10
TW202246347A (zh) 2022-12-01
CN116655790A (zh) 2023-08-29
US11203637B2 (en) 2021-12-21
EP3504243A4 (en) 2020-03-11
TWI769174B (zh) 2022-07-01
JP6968872B2 (ja) 2021-11-17
CA3034962A1 (en) 2018-03-01
EP3970749A1 (en) 2022-03-23
US20220135675A1 (en) 2022-05-05
KR102460525B1 (ko) 2022-11-01
US20190276533A1 (en) 2019-09-12
JP2019529373A (ja) 2019-10-17
MX2019002242A (es) 2019-08-16
KR20190042037A (ko) 2019-04-23
JP7158552B2 (ja) 2022-10-21
EA201990594A1 (ru) 2019-08-30
AU2017317227A1 (en) 2019-04-11
SG10201912199XA (en) 2020-02-27
CN116478290A (zh) 2023-07-25
US20240076375A1 (en) 2024-03-07
WO2018036561A1 (en) 2018-03-01
TW201819414A (zh) 2018-06-01

Similar Documents

Publication Publication Date Title
BR112019003976A2 (pt) anticorpos anti-tim-3 e seu uso
BR112016016436A2 (pt) moléculas de anticorpo para tim-3 e usos das mesmas
BR112018012138A2 (pt) moléculas de anticorpo para pd-1 e usos das mesmas
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
EA201691765A1 (ru) Молекулы антител против lag-3 и их применения
MX2018008369A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112018072389A2 (pt) anticorpos que reconhecem tau
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112017016330A2 (pt) anticorpos anti-transtiretina
WO2017019894A8 (en) Combination therapies comprising antibody molecules to lag-3
BR112018072394A2 (pt) anticorpos que reconhecem a tau
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
BR112017016324A2 (pt) anticorpos anti-transtiretina
BR112017016345A2 (pt) anticorpos anti-transtiretina
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
BR112021025421A2 (pt) Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
BR112021023540A2 (pt) Agentes de afinidade
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
MA39336B1 (fr) Molécules d'anticorps anti-lag-3 et leurs utilisations
MX2020013798A (es) Moléculas de anticuerpo de componente de complemento 5 y sus usos.
MA39221B1 (fr) Molécules d'anticorps anti-tim-3 et leurs utilisations

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]